Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an initial financial grant supporting the launch of Life's a Polyp Foundation, the first U.S. patient advocacy group focused exclusively on Familial Adenomatous Polyposis (FAP).
Biodexa highlighted its lead program eRapa, an encapsulated rapamycin in the registrational Phase 3 Serenta trial with >20% enrollment and FDA Fast Track designation, and said the grant aims to boost patient resources, community support, and awareness for FAP patients and families.
Positive
- Initial grant funds establishment of first U.S. FAP patient advocacy group
- Lead program eRapa in registrational Phase 3 Serenta with >20% patient enrollment and FDA Fast Track designation
Negative
- None.
News Market Reaction – BDRX
On the day this news was published, BDRX gained 4.86%, reflecting a moderate positive market reaction. This price movement added approximately $38K to the company's valuation, bringing the market cap to $819,411 at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BDRX was down 4.37% while several biotech peers were up (e.g., QLGN +7.72%, SLXN +4.85%, DRMA +3.36%, GLTO +1.8%; ENTO -5.68%). This mix, with most peers positive, points to stock-specific dynamics rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Licensing deal | Positive | +3.2% | License of Phase 1–ready MTX240 for GIST from Otsuka. |
| Feb 04 | Licensing deal | Positive | -11.0% | Exclusive license of Otsuka’s OPB-171775 (MTX240) for GIST. |
| Jan 05 | Leadership change | Neutral | +2.0% | Promotion of Fiona Sharp to CFO, Company Secretary, and director. |
| Dec 18 | Equity offering | Negative | -24.0% | Pricing of approximately $10M public offering with ADS and pre-funded units. |
| Dec 01 | Clinical trial update | Positive | +2.2% | First European patients enrolled into pivotal Phase 3 Serenta FAP trial. |
BDRX has generally reacted positively to clinical milestones and negatively to financing, with one notable divergence on a licensing announcement.
Over the last six months, Biodexa has focused on gastrointestinal oncology and capital raising. Licensing deals with Otsuka for MTX240 on Feb 4 and Feb 19, 2026 expanded its GIST pipeline alongside the Phase 3 eRapa FAP program. A pivotal Serenta trial update on Dec 1, 2025 and a CFO/Board appointment on Jan 5, 2026 marked operational progress. A $10.0 million public offering on Dec 18, 2025 coincided with a sharp negative price reaction. Today’s advocacy-support news fits the ongoing FAP-focused, patient-centric narrative.
Market Pulse Summary
This announcement emphasizes Biodexa’s support for the first U.S.-based FAP advocacy foundation and reinforces alignment between the Phase 3 eRapa Serenta program and patient needs. Recent history shows pipeline expansion in GIST, a pivotal FAP trial with a $20 million grant, and a dilutive $10.0 million offering. Investors may watch future Serenta enrollment milestones, additional advocacy collaborations, and any further capital-raising steps as key markers of execution and balance-sheet management.
Key Terms
familial adenomatous polyposis medical
rapamycin medical
phase 3 medical
progression free survival medical
fast track designation regulatory
AI-generated analysis. Not financial advice.
March 9, 2026
Biodexa Announces Support for Life’s a Polyp Foundation
First U.S. Patient Advocacy Group for FAP Patients
Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP).
The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic condition that causes hundreds of precancerous polyps and carries a near
Biodexa's mission is to address unmet needs in FAP, exemplified by its lead program eRapa, a proprietary encapsulated rapamycin currently in the registrational Phase 3 Serenta trial—the first potential non-surgical treatment to increase progression free survival in FAP, with over
Biodexa remains dedicated to patient-centric initiatives and looks forward to ongoing collaboration with the foundation to amplify patient voices in rare disease research and care.
For more information, please contact:
Biodexa Pharmaceuticals PLC |
| Steve Ellul, CBO |
| Tel: +44 (0)29 20480 180 |
| www.biodexapharma.com |
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
About Life's a Polyp Foundation
The Life's a Polyp Foundation is a new U.S.-based nonprofit dedicated to supporting FAP patients through education, advocacy, research funding, and community building. Learn more at www.lifesapolyp.org.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
FAQ
What support did Biodexa (BDRX) announce for Life's a Polyp Foundation on March 9, 2026?
How does Biodexa say its eRapa program relates to the Life's a Polyp Foundation partnership?
What is the clinical status of Biodexa's eRapa (BDRX) as of March 9, 2026?
Does Biodexa (BDRX) describe eRapa as a potential non-surgical treatment for FAP?
How can patients or investors learn more about Biodexa's support for Life's a Polyp Foundation?
